Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses. TAK-003 is currently in Phase 3 development and being investigated for the prevention of dengue.
Takeda partnered with the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) and global vaccine developers to rapidly and sustainably supply COVID-19 vaccines in Japan.
Takeda’s Zika vaccine candidate (TAK-426) is an inactivated, adjuvanted, whole Zika virus vaccine and will begin Phase 2 development in mid-CY2022. TAK-426 is being developed with support from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
Takeda’s vaccine (BLB-750) is an injectable, whole virion, cell culture-based pandemic influenza vaccine to protect against H5N1. BLB-750 was approved (1mL vials) in Japan in 2014 followed by new formulations (5mL multi dose vials and 0.5mL pre-filled syringes) approved in 2018.
* Takeda has a measles-rubella combined vaccine, a measles vaccine and a rubella vaccine on the Japanese market.
+ Takeda has a diphtheria-tetanus combined vaccine and a tetanus-toxoid vaccine on the Japanese market.
ϒ Takeda’s varicella vaccine has been approved for an additional indication treating herpes-zoster.